



Info: info@igbamedicines.org

Calling for health and access to health for all as a priority in the upcoming G7 Leaders' Summit – An IGBA perspective

Geneva, June 13, 2024

For immediate release

The [International Generic and Biosimilar medicines Association \(IGBA\)](https://www.igbamedicines.org/), being the global voice of generic and biosimilar medicines industries, calls for G7 countries to consider health and access to health as a priority in its upcoming discussions, to be held in Alberta, Canada.

In a world reordering its priorities and facing mounting economic and societal challenges and uncertainty, health should be recognized as an essential part of functional societies and economies. The G7 faces a unique opportunity to advance broad access to safe, effective, cost-effective, and quality-assured therapies to patients.

To do this, the G7 Leaders' Summit should consider the following points:

- **Harnessing the social and economic value of generics and biosimilars:** Generic medicines represent [between 70 and 90% of medicines dispensed in most G7-countries](#) with reduced impact on healthcare budgets. In a context of tight fiscal and financial conditions, safe, efficacious, cost-effective, and quality-assured medicines represent an opportunity to work towards ensuring widespread access to all. Policies aiming at harmonizing regulatory requirements, guaranteeing pro-competition frameworks, and securing industry's financial viability are essential to this end.
- **Future-proofing supply chains:** globally integrated supply chains are essential for the appropriate flow of cost-effective, quality-assured medicines. Their disruption will have an impact on patients' access to life-saving medicines, as shortages are likely to be created. The Summit will be an invaluable opportunity to explore ways to increase its sustainability and resiliency.
- **Balancing intellectual property systems:** As real innovation drives progress, we share the view that it deserves to be rewarded through intellectual property protections, namely quality patents. Once these expire, widespread timely access to these innovations should ensue. Working towards ensuring quality in patents granted and reducing delays in market entry of pharmaceutical competition once they expire are essential elements to the progress and well-being of societies.

The IGBA, as the global voice of generic and biosimilar medicines, reiterates its patient-centric approach and its vision of improving patients' access to quality-assured, safe, and cost-effective medicines by balancing the protection of innovation with the promotion of timely competition in the pharmaceutical sector and sustainable economic contributions for all stakeholders. We remain a committed partner to the G7 countries in their efforts to increase patient access to life-saving medicines.

About IGBA: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients' access to quality assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org